

This material is an English translation of the press release announced on February 8, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.

February 8, 2018

Announcement of Establishment of New Company

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that Hisamitsu has resolved to establish a new company in Hong Kong, Hisamitsu Pharmaceutical (Hong Kong) Co., Limited at the board of directors' meeting held on February 8, 2018.

1. Purpose of establishment

To ensure future growth of Hisamitsu group, Hisamitsu has decided to establish a new company with following overview in the important market, Hong Kong, for the purpose of strengthening sales of Hisamitsu products such as “Salonpas®” and “Mohrus® Patch” in Hong Kong.

2. Overview of the new company

- (1) Name of the company: Hisamitsu Pharmaceutical (Hong Kong) Co., Limited (Tentative name)
(久光製薬(香港)有限公司) (予定)
- (2) Location: Kowloon, Hong Kong,
- (3) Representative Director: Kyu Saito (Director & Executive Officer, Head of International Division, Hisamitsu Pharmaceutical Co., Inc.)
- (4) Contents of business: Import and sales of pharmaceutical products
- (5) Capital: 10 million yen
- (6) Shareholding ratio: Hisamitsu Pharmaceutical Co., Inc. 100%
- (7) Date of Establishment: February 2018 (tentative)

The impact on earnings for the fiscal year ending February 28, 2018 is to be negligible. Therefore no change is made on forecast. Service details or forecast will be announced promptly, if any changes were made.



Delivering Patch Culture Hand by Hand

Hisamitsu Pharmaceutical Co., Inc. was established in 1847 and has marked its 170th anniversary since its foundation thanks to the support of many people.